Restrictive Lung Diseases Flashcards

(38 cards)

1
Q

What is restrictive lung disease?

A

Lung volumes are small
Expansion of the lung restricted by……

Intrinsic lung disease -
—alterations to lung parenchyma interstitial lung disease (ILD)

Extrinsic disorders -
compress lungs or limit expansion
—Pleural
—Chest wall
—-Neuromuscular (decrease ability of respiratory muscles to inflate / deflate the lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the important cellular components of the lung parenchyma?

A

Lung parenchyma = the alveolar regions of the lung

Alveolar type 1 epithelial cell – gas exchange surface (approx. 70m2)

Alveolar type 2 epithelial cell – surfactant to reduce surface tension, stem cell for repair

Fibroblasts – produce extracellular matrix (ECM) e.g Collagen type 1

Alveolar macrophages – phagocytose foreign material, surfactant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the interstitial space?

A

Space between alveolar epithelium and capillary endothelium.
—Contains lymphatic vessels, occasional fibroblasts and ECM
—-Structural support to lung
—-Very thin (few micrometers thick) to facilitate gas exchange

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does interstitial lung disease involve?

A

Inflammation or fibrosis in the interstitial space

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the types of interstitial lung diseases?

A

Idiopathic
Auto-immune related
Exposure related
With cysts or airspaces filling
Sarcoidosis
Others e.g. eosinophilic pneumonia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the clinical presentation in terms of history for ILD?

A

Progressive breathlessness

Non-productive cough

Limitation in exercise tolerance

Symptoms of connective tissue disease?

Occupational and exposure history

Medication history (drug induced ILD, http://www.pneumotox.com)

Family history (up to 20% of idiopathic ILDs are familial)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the clinical presentation in terms of clinical examination in ILD?

A

Low oxygen saturations (resting or exertion)

Fine bilateral inspiratory crackles

Digital clubbing

(+/- features of connective tissue disease – skin, joints, muscles)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the investigations for ILD?

A

Blood tests e.g. anti-nuclear antibody (ANA), rheumatoid factor (RhF), anti-citrullinated peptide (CCP)

Pulmonary function tests

6-minute walk test (6MWT) – SpO2 ≤ 88% associated with increased risk of death

High-resolution CT scan (HRCT)

Invasive testing:

—–Bronchoalveolar lavage (BAL)

—–Surgical lung biopsy (2-4% mortality)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Explain the lung physiology in ILD

A

Scarring makes the lung stiff - ↓ lung compliance

↓ Lung volumes (TLC, FRC, RV)

↓ FVC

↓ diffusing capacity of lung for carbon monoxide (DLCO)

↓ arterial PO2 – particularly with exercise

Normal or ↑ FEV1/ FVC ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Look at patterns of forced expiration**

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does a High-resolution CT (HRCT) work?

A

CT uses X-rays to obtain cross-sectional images
Rotating X-ray source and detectors spin around the patient gathering data
HRCT - thin slices and high-frequency reconstruction – gives good resolution at level of secondary pulmonary lobule (smallest functional lung unit identifiable on CT)

High - density substances e.g. bone absorb more x-rays and appear whiter
Low - density substances e.g. air absorb few x-rays and appear darker

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Look at HRCT patterns in pneumonia**

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Who in the MDT is involved in diagnosis?

A

Integration of clinical, radiological +/- pathological information to make a diagnosis

Radiologist
Clinical nurse specialist
Physiotherapist/occupational therapist
Pulmonologist
Respiratory physiologist
Pathologist
Rheumatologist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the variables evaluated during an MDT?

A

Clinical information
Environmental exposures
Biology and autoimmunity
Familial history / genetic information
PFT
CT
Serological testing
Biopsy
Bronchoscopy / BAL
Longitudinal ILD evolution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are general principles of ILD management in terms of early disease?

A

Pharmacological therapy – immunosuppressive drugs, antifibrotics
Clinical trials
Patient education
Vaccination
Smoking cessation
Treatment of co-morbidities – gastroesophageal reflux, obstructive sleep apnoea, pulmonary hypertension
Pulmonary rehabilitation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are general principles of ILD management in terms of late disease?

A

Supplemental oxygen
Lung transplantation
Palliative care – symptom management, end-of-life care

17
Q

What is idiopathic pulmonary fibrosis (IPF)?

A

Progressive, scarring lung disease of unknown cause

6,000 new cases diagnosed each year

1% of all deaths in UK

Incidence increases with age - most >60yrs

More common in men

Average decline in forced vital capacity (FVC) = 150 – 200mls / year

18
Q

What is the prognosis of IPF?

A

Median untreated survival 3 - 5 years

19
Q

What are the proposed mechanisms of IPF

A

Predisposing factors

Genetic susceptibility
-MUC5B, DSP

Environmental triggers
-smoke, viruses, pollutants, dusts

Cellular ageing
-telomere attrition, senescence

20
Q

What is IPF initiated by?

A

Alveolar epithelial injury

Denuded alveolar epithelium seen by electron microscopy

Targeted injury to AECIIs in mouse model – ↑ collagen deposition

Re-epithelialization disturbed in IPF

21
Q

Look at the histopathology of IPF**

A

Microscopic honeycomb cyst

Fibroblastic foci

22
Q

What are the characteristic features of IPF on CT scan?**

A

Axial plane - subpleural honeycombing
-traction bronchiectasis

Coronal plane- basal predominance

23
Q

What is harmful in IPF?

A

Immunosuppression

24
Q

What do antifibrotics do in IPF?

A

Slows disease progression but do not cure

e.g. nintedanib - tyrosine kinase inhibitor
-pirfenidone - a pyridine compound

25
What do drugs target in fibrotic pathways in clinical trials***
26
What is hypersensitivity pneumonitis ?
-ILD caused by immune- mediated response in susceptible and sensitised individuals to inhaled environmental antigens -Genetic and host factors may explain why only few exposed individuals get HP -Involves small airways and parenchyma
27
What is acute HP?
Intermittent, high-level exposure – abrupt symptom onset, flu-like syndrome 4-12 hrs after exposure
28
What is chronic HP?
Long-term, low-level exposure Nonfibrotic (purely inflammatory) Fibrotic – associated with higher mortality
29
What is the mean onset age for HP? Does smoking increases frequency?
50-60yrs Yes
30
How is HP driven by immunological dysregulation?
-Antigen exposure and processing by the innate immune system -Inflammatory response mediated by T-helper cells and antigen-specific immunoglobulin (Ig) G antibodies -Accumulation of lymphocytes and formation of granulomas
31
Explain the diagnostic work up of HP
Detailed exposure history – antigen not identified in ~50%1 Inspiratory ‘squeaks’ on auscultation - caused by the coexisting bronchiolitis Specific circulating IgG antibodies (serum precipitins) to potential antigens HRCT Bronchoalveolar lavage (BAL) lymphocyte count >30%2
32
What is the treatment of HP?
Complete antigen removal / avoidance is crucial Corticosteroids often used Immunosuppressants e.g. mycophenolate mofetil (MMF) and azathioprine used but poor evidence base Progressive, fibrotic HP – Nintedanib (antifibrotic)
33
What is Systemic sclerosis associated (SSc) ILD?
SSc is an autoimmune connective tissue disease characterised by immune dysregulation and progressive fibrosis that affects skin, with variable internal organ involvement Affects young, middle-aged women ILD develops in 30-40 % and is most common cause of death – 10-year mortality of 40% Slow indolent course vs. rapid progression Male, older age, smoker, >20% extent on HRCT, FVC <70%  worse survival
34
What are the clinical features of SSc?
Classified based on skin involvement - limited cutaneous SSc (Pulmonary hypertension more common) or diffuse cutaneous SSc (ILD more common) Autoantibodies – ---Anti-centromere ---Anti-Scl-70 - associated with increased with ILD
35
Explain further using images what the clinical features of SSc are? ***
Sclerodactyly Raynaud’s Telengectasias Abnormal nailfold capillaroscopy Digital ulcer
36
Explain the pathogenesis of ILD?***
Tissue injury Vascular injury Autoimmunity Inflammation Fibrosis
37
What are HRCT patterns in SSc-ILD?**
Non-specific interstitial pneumonia (NSIP) pattern is the most common pattern
38
What is the management of SSc-ILD?
Determined by disease extent on HRCT and lung function trajectory (monitor every 3 – 6 months) Corticosteroid use is controversial and risk of renal crisis with high doses (>10mg/day) Immunosuppressives – cyclophosphamide, mycophenolate mofetil (MMF)1 Progressive fibrotic phenotype– Nintedanib (antifibrotic)2